From the Journals

PCPs lag on albuminuria tests in patients with type 2 diabetes


 

FROM DIABETES CARE

U.S. primary care physicians are not properly checking patients with type 2 diabetes for chronic kidney disease (CKD) nearly as often as they should, meaning many of these patients miss getting a timely diagnosis.

Mr. Nikita Stempniewicz, director of research and analytics, American Medical Group Association, Alexandria, Va

Nikita Stempniewicz

Inadequate measurement of urinary albumin-to-creatinine ratio (uACR) is the issue.

Review of data from more than half a million U.S. primary care patients with type 2 diabetes seen at any of 1,164 practice sites run by any of 24 health care organizations during 2016-2019 showed that barely more than half, 52%, had both their uACR and estimated glomerular filtration rate (eGFR) checked annually as recommended by several U.S. medical societies, and just 73% had both values checked during a 3-year period, Nikita Stempniewicz, MSc, and associates reported in Diabetes Care.

More detailed data showed that measurement of eGFR was reasonably robust, measured at a 90% rate annually and in 97% of patients at least once every 3 years. But recording uACR values lagged, with a 53% annual rate and a 74% rate of measurement at least once every 3 years, reported Mr. Stempniewicz, director of research and analytics for the American Medical Group Association, a trade association based in Alexandria, Va. The 24 health care organizations that supplied the study’s data are all members of this association.

Prevailing recommendations from various medical societies call for annual monitoring of urinary albumin in patients with type 2 diabetes and specify the uACR, such as in the Standards of Medical Care in Diabetes from the American Diabetes Association, as well as in recommendations promoted by the National Kidney Foundation.

Missing half the CKD patients with eGFR only

“Half the patients with type 2 diabetes and chronic kidney disease have elevated albuminuria without decreased eGFR and would not be detected with eGFR testing alone,” Mr. Stempniewicz noted in an interview.

“Many patients who present for nephrology care are incompletely assessed with only low eGFR but no urine testing. Missing albuminuria testing and uACR values means patients with high levels of albuminuria but normal kidney function go undetected and thus are not able to benefit from evidenced-based interventions, including nephrology services,” said Joseph A. Vassalotti, MD, a nephrologist, chief medical officer for the National Kidney Foundation, and a coauthor of the report.

Dr. Josef Koresh, professor of clinical epidemiology, Johns Hopkins School of Public Health, Baltimore

Dr. Josef Coresh

Not testing patients with type 2 diabetes regularly for their uACR “is a missed opportunity to identify the highest-risk patients and treat them,” added Josef Coresh, MD, PhD, a professor of clinical epidemiology at Johns Hopkins University, Baltimore, and senior author on the study. Measurement of albuminuria is especially important for these patients because medications from the sodium-glucose cotransporter 2 inhibitor class have been proven to slow progression of CKD in patients with type 2 diabetes, but these drugs are expensive, and in some cases have labeling that specifies the presence of albuminuria.

“I have no doubt that improving albuminuria testing is a critical step to identify patients with diabetes at highest risk who should get the best treatment possible, including SGLT2 inhibitors,” Dr. Coresh said in an interview.

The new report is not the first to document inadequate assessment of albuminuria and uACR among primary care physicians (PCPs), but it came from the largest reported U.S. study to date. “eGFR is commonly collected in a routine laboratory blood panel, but collecting urine requires additional work flow,” noted Cara B. Litvin, MD, a general internal medicine researcher at the Medical University of South Carolina, Charleston, who has tested interventions aimed at boosting CKD assessment by PCPs and was not involved in the new study.

“There have also been conflicting guidelines,” such as a “now-inactive guideline from the American College of Physicians that recommended against routine urine albumin screening in patients with diabetes and already on treatment with an angiotensin converting enzyme inhibitor or an angiotensin receptor blocker,” she said.

Pages

Recommended Reading

FDA rejects teplizumab for type 1 diabetes delay
Journal of Clinical Outcomes Management
Pandemic upped telemedicine use 100-fold in type 2 diabetes
Journal of Clinical Outcomes Management
New drug, finerenone, approved for slowing kidney disease in diabetes
Journal of Clinical Outcomes Management
South Asian ancestry associated with twice the risk of heart disease
Journal of Clinical Outcomes Management
Not so crazy: Pancreas transplants in type 2 diabetes rising
Journal of Clinical Outcomes Management
ADA/EASD draft guidance aims to bring adults with type 1 diabetes out of shadows
Journal of Clinical Outcomes Management
Cycling linked to longer life in people with type 2 diabetes
Journal of Clinical Outcomes Management
FDA OKs spinal cord stimulation for diabetic neuropathy pain
Journal of Clinical Outcomes Management
FDA okays extended-release exenatide for children with T2D
Journal of Clinical Outcomes Management
Diabetes duration linked to increasing heart failure risk
Journal of Clinical Outcomes Management